Clozapine for the treatment of psychosis in Parkinson's disease: A review

Acta Neurologica Scandinavica

Volumn 94, Issue 5, 1996, Pages 329-336

  Auzou, P ^a,b   Ozsancak C ^a   Hannequin, D ^a   Moore, N ^b   Augustin, P ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Clozapine; Drug induced psychosis; Parkinson's disease; Treatment

Indexed keywords

ANTIPARKINSON AGENT; CLOZAPINE;

ADOLESCENT; ADULT; AGED; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PSYCHOSIS; REVIEW; SEDATION;

EID: 0029799371     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1996.tb07075.x     Document Type: Review

References (76)

1. FACTOR SA, BROWN D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992: 7: 125-01.
2. SAINT-CYR JA, TAYLOR AE, LANG AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 1993: 43 (Suppl. 6): S47-S52.
3. DANIELCZYK W. Mental disorders in Parkinson's Disease. J Neural Transm Park Dis Dement Sect 1992: 38 (suppl): 115-127.
4. RONDOT R, DE RECONDO J, COIGNET A, ZIEGLER M. Mental disorders in Parkinson's disease after treatment with L-dopa. Adv Neurol 1984: 40: 259-269.
5. LUDIN HP. (1988) Das Parkinsonsyndrom. In: Baumgartner G, Cohen R, Grüsser OJ, Helmchen H, Schmidt LR (Hrsg) Kohlhammer, Stuttgart Berlin: Köln Mainz, S104.
6. MAYEUX R, CHEN J, MIRABELLO E et al. An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology 1990: 40: 1513-1517.
7. SACKS OW, KOHL MS, MESSELOFF CR, SCHWARTZ WF. Effects of levodopa in parkinsonian patients with dementia. Neurology 1972: 22: 516-519.
8. CUMMINGS JL. Behavioral complications of drug treatments of Parkinson's disease. J Am Geriatr Soc 1991: 39: 708-716.
9. STERN Y, MARDER K, XI TANG M, MAYEUX R. Antecedent clinical features associated with dementia in Parkinson's disease. Neurology 1993: 43: 1690-1692.
10. PEDERZOLI M, GIROTTI F, SCIGLIANO G, et al. L-Dopa long-term treatment in Parkinson's disease: age-related side-effects. Neurology 1983: 33: 1518-1522.
11. LIEBERMAN A, GOLDSTEIN M, LEIBOWITZ M, NEOPHYTIDES A, KUPERSMITH M, PACT V, KLEINBERG D. Treatment of advanced Parkinson's disease with pergolide. Neurology 1981: 31: 675-682.
12. STERN Y, MAYEUX R, ILSON J, FAHN S, COTE L. Pergolide therapy for Parkinson's disease: Neurobehavioral changes. Neurology 1984: 34: 201-204.
13. DE SMET Y, RUBERG M, SERDARU M, DUBOIS B, LHERMITTE F, AGID Y. Confusion, dementia and anticholinergics in Parkinson's Disease. J Neurol Neurosurg Psych 1982: 45: 1161-1164.
14. GREENE P, COTE L, FAHN S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol 1993: 60: 703-6.
15. FRIEDMAN JH. The management of the levodopa psychoses. Clin Neuropharmacol 1991: 14: 283-295.
16. SCHOLZ E, DICHGANS J. Treatment of drug-induced exogenous psychosis in Parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Clin Neurosci 1985: 235: 60-64.
17. FARDE L, WIESEL FA, HALLDIN C, SEDVALL G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiary 1988: 45: 71-78.
18. SMITH M, WOLF AP, BRODIE JD, et al. Serial [18F]N-methylspiperone PET studies to measure changes in antipsychotic drug D2 receptor occupancy in schizophrenic patients. Biol Psychiatry 1988: 23: 653-663.
19. BARON JC, MARINOT JL, CAMBON H, et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactine levels. Psychopharmacology 1989: 99: 463-472.
20. GERLACH J, HANSEN L. Clozapine and D1/D2 antagonism in extrapyramidal functions. Br J Psychiatry 1992: 160 (Suppl. 17): 34-37.
21. FARDE L, NORDSTRÖM AL, WIESEL FA, PAULI S, HALLDIN C, SEDVALL G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with neuroleptics and clozapine. Arch Gen Psychiatry 1992: 49: 538-544.
22. VAN TOL HHM, BUNZOW JR, GUAN HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991: 350: 610-614.
23. VAN TOL HHM, WU CM, GUAN HC, et al. Multiple dopamine D4 receptor variants in the human population. Nature 1992: 358: 149-152.
24. REYNOLDS GP. The importance of dopamine D4 receptors in the action and development of antipsychotic agents. Drugs 1996: 51: 7-11.
25. CANTON H, VERRIELE L, COLPAERT FC. Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HT1C sites. Eur J Pharmacol 1990: 191: 93-96.
26. BALDESSARINI RJ, FRANKENBURG FR. Clozapine: A novel antipsychotic agent. N Engl J Med 1991: 324: 746-754.
27. COWARD DM. General pharmacology of clozapine. Br J Psychiatry 1992: 160 (Suppl. 17): 5-11.
28. MELTZER HY. The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry 1992: 160 (Suppl. 17): 22-29.
29. MASON SL, REYNOLDS GP. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. Eur J Pharmacol 1992: 221: 397-398.
30. FRIEDMAN JH, LANNON MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989: 39: 1219-1221.
31. PFEIFFER RF, KANG J, GRABER B, HOFMAN R, WILSON J. Clozapine for psychosis in Parkinson's disease. Mov Disord 1990: 5: 239-242.
32. AUZOU P, HANNEQUIN D, LANDRIN I, COCHIN JP, MOORE N. Worsening of psychotic symptoms by clozapine in Parkinson's disease. Lancet 1994: 344: 955.
33. FACTOR SA, BROWN D, MOLHO ES, PODSKALNY GD. Clozapine: A 2-year open trial in Parkinson's disease patients with psychosis. Neurology 1994: 44: 544-546.
34. LINAZASORO G, SUAREZ JA, MARTI MASSO JF. Clozapine in Parkinson's disease : three years experience. Mov Disord 1992: 7 (Suppl. 1): 100.
35. PINTER MM, HELSCHER RJ. Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. J Neural Transm Park Dis Dement Sect 1993: 5: 135-46.
36. WOLTERS E, HURWITZ TA, MAK E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990: 40: 832-834.
37. KAHN N, FREEMAN A, JUNCOS JL, MANNING D, WATTS RL. Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 1991: 41: 1699-1700.
38. MELTZER HY, KENNEDY J, DAI J, PARSA M, RILEY D. Plasma clozapine levels and the treatment of L-Dopa-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacology 1995: 12: 39-45.
39. DIEDERICH N, KEIPES M, GRAAS M, METZ H. La clozapine dans le traitement des manifestations psychiatriques de la maladie de Parkinson. Rev Neurol 1995: 151: 251-257.
40. ROBERTS HE, DEAN RC, STOUDEMIRE A. Clozapine treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1989: 1: 190-192.
41. WOLK SI, DOUGLAS CJ. Clozapine treatment of psychosis in Parkinson's disease: A report of five consecutive cases. J Clin Psychiatry 1992: 53: 373-376.
42. GREENE P. Clozapine therapeutic plunge in patient with Parkinson's disease. Lancet 1995: 345: 1172-1173.
43. LEW MF, WATERS CH. Clozapine treatment of parkinsonism with psychosis. J Am Geriatr Soc 1993: 41: 669-71.
44. Friedman JH. Management of psychosis in Parkinson's disease. In: Koller WC, Paulson G, eds. Therapy of Parkinson's disease. New York: Marcel Dekker, INC, 1995: 521-532.
45. ROSENTHAL SH, FENTON ML, HARNETT DS. Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease. Gen Hosp Psychiatry 1992: 14: 285-286.
46. GONSKI PN. The use of clozapine in Parkinson's disease. Aust NZ J Med 1994: 24: 585.
47. BERNARDI F, DEL ZOMPO M. Clozapine in idiopathic Parkinson's disease. Neurology 1990: 40: 1151-2.
48. PAKKENBERG H, PAKKENBERG B. Clozapine in the treatment of tremor. Acta Neurol Scand 1986: 73: 295-7.
49. FRIEDMAN JH, LANNON MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990: 5: 225-9.
50. FISCHER PA, BAAS H, HEFNER R. Treatment of parkinsonian tremor with clozapine. J Neural Transm Park Dis Dement Sect 1990: 2: 233-238.
51. FRIEDMAN JH, LANNON NC, CALEY C. Clozapine for movement disorder patients: A retrospective analysis of 38 patients. Ann Neurol 1992: 32: 277.
52. JANSEN ENH. Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol Scand 1994: 89: 262-265.
53. OSTERGAARD K, DUPONT E. Clozapine treatment of drug-induced psychotic symptoms in late stages of Parkinson's disease. Acta Neurol Scand 1988: 78: 349-50.
54. GERSHANIK O, GARCIA S, PAPA S, SCIPIONI O. Analysis of the mechanism of action of clozapine in Parkinson's disease. Mov Disord 1992: 7 (Suppl 1): 101.
55. RABEY JM, TREVES TA, NEUFELD MY, ORLOV E, KORCZYN AD. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995: 45: 432-434.
56. RUI SILVA M, MAGALHAES M, VISEU M, BASTOS LIMA A. Clozapine in the treatment of psychosis in Parkinsonism. J Neurol 1995: 242 (Suppl 2): 138.
57. BENNETT JP, LANDOW ER, SCHUH LA. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993: 43: 1551-1555.
58. BENNETT JP, LANDOW ER, DIETRICH S, SCHUH LA. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dykinesia reduction. Mov Disord 1994: 9: 409-414.
59. AREVALO GJG, GERSHANIK OS. Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study. Mov Disord 1993: 8: 349-354.
60. LINAZASORO G, MARTI MASSO JF, SUAREZ JA. Nocturnal akathisia in Parkinson's disease: Treatment with clozapine. Mov Disord 1993: 8: 171-174.
61. COPP PJ, LAMENT R, TENNENT TG. Amitriptyline in clozapine-induced sialorrhoea. Br J Psychiatry 1991: 159: 166.
62. GRABOWSKI J. Clonidine treatment of clozapine-induced hypersalivation. J Clin Psychopharmacol 1992: 12: 69-70.
63. FRITZE J, ELLIGER T. Pirenzepine for clozapine-induced hypersalivation. Lancet 1995: 346: 1034.
64. ZORN SH, JONES SB, WARD KM, LISTON DR. Clozapine is a potent and selective muscarinic M-4 receptor antagonist. Eur J Pharmacol Mol Pharmacol 1994: 269: R1-R2.
65. SIMPSON GM, COOPER TA. Clozapine plasma levels and convulsions. Am J Psychiatry 1978: 135: 99-100.
66. DEVINSKY O, HONIGFELD G, PATIN J. Clozapine-related seizures. Neurology 1991: 41: 369-371.
67. WOLTERS E, HURWITZ TA, PEPPARD FR, CALNE DB. Clozapine: an antipsychotic agent in Parkinson's disease? Clin Neuropharmacol 1989: 12: 83-90.
68. MILLER DD, SHARAFUDDIN M, KATHOL R. A case of clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry 1991: 52: 99-101.
69. ANDERSON ES, POWERS PS. Neuroleptic malignant syndrome associated with clozapine use. J Clin Psychiatry 1991: 52: 102-104.
70. DASGUPTA K, YOUNG A. Clozapine-induced neuroleptic syndrome. J Clin Psychiatry 1991: 52: 105-107.
71. ALVIR JMJ, LIEBERMAN JA, SAFFERMAN AZ, SCHWIMMER JL, SCHAAF JA. Clozapine-induced agranulocytosis. N Engl J Med 1993: 329: 162-167.
72. SALZMANN C. Mandatory monitoring for side effect. The 'burdening' of clozapine. N Engl J Med 1990: 323: 827-829.
73. KIRKEGAARD A, HENSEN A. An investigation of some side effects in 47 psychotic patients during treatment with clozapine and discontinuing of the treatment. Arzneim-Forsch Drug Res 1979: 29: 851-858.
74. CATES M, LUSK K, WELLS BG. Nonleukopenic neutropenia in a patient treated with clozapine. N Engl J Med 1992: 326: 840-841.
75. BURKE WJ, RANNO AE. Neutropenia with clozapine and methazolamide. J Clin Psychopharmacol 1994: 14: 357-358.
76. RYABIK BM, NGUYEN VT, MANN RM, SMITH JD, LIPPMAN SB. Clozapine-induced agranulocytosis and colony stimulating cytokines. Gen Hosp Psychiatry 1993: 15: 263-265.